Cystic Fibrosis

Cystic Fibrosis — scientific infographic poster
🌬️ Interactive Visualization The Airway Escalator & Cough — sweep the lungs clean Watch millions of cilia sweep a mucus blanket of trapped dust and germs up and out of your lungs — then trigger a cough to blast an irritant clear, or light a cigarette and watch the escalator freeze. Launch → 🫛 Interactive Visualization Inheritance: Dominant, Recessive and Punnett Squares Cross two parents and watch alleles sort into a Punnett square — flip dominance and carrier status to see why two unaffected parents can have an affected child. Launch → ✂️ Interactive Visualization CRISPR: How Gene Editing Works Program a guide RNA, watch Cas9 find its match and cut both DNA strands — then let the cell repair it to knock a gene out or paste a healthy one in. Launch →

Table of Contents

  1. What Cystic Fibrosis Is
  2. Causes of Cystic Fibrosis
  3. Common Symptoms of Cystic Fibrosis
  4. Complications of Cystic Fibrosis
  5. Diagnosis
  6. Treatment Options
  7. Prevention and Management Strategies
  8. Living with Cystic Fibrosis
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What Cystic Fibrosis Is

Cystic fibrosis (CF) is a genetic disorder that primarily affects the lungs and digestive system. It is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, leading to the production of thick, sticky mucus that can clog the airways and trap bacteria, resulting in repeated lung infections and breathing difficulties. CF can also affect the pancreas, liver, and other organs, leading to a variety of health complications.

Causes of Cystic Fibrosis

Common Symptoms of Cystic Fibrosis

Complications of Cystic Fibrosis

Diagnosis

Treatment Options

Triple-combination trials. Nearly 90% of people with cystic fibrosis carry at least one copy of the most common CFTR mutation, Phe508del (also written F508del). In a 2019 trial of 403 people aged 12 and older with one Phe508del copy and a second, minimal-function mutation, elexacaftor-tezacaftor-ivacaftor gave lung function (FEV1, the air blown out in one second, as a percentage of the expected value) 14.3 percentage points higher than placebo through 24 weeks, 63% fewer flare-ups (pulmonary exacerbations), and sweat chloride 41.8 mmol per liter lower; most side effects were mild or moderate, and 1% stopped the drug because of them.

Vanzacaftor-tezacaftor-deutivacaftor is taken once a day, against twice a day for elexacaftor-tezacaftor-ivacaftor. In two 52-week phase 3 trials published in 2025 (971 people aged 12 and older), it matched elexacaftor-tezacaftor-ivacaftor on lung function (a difference of 0.2 percentage points), with mostly mild or moderate side effects. A 2026 open-label study in 67 children aged 2–5 found that 92% reached a sweat chloride below the cystic fibrosis diagnostic threshold of 60 mmol/L after 24 weeks; no child stopped because of side effects. The triple-combination trials described here were all funded by the drugs’ maker.

Prevention and Management Strategies

Living with Cystic Fibrosis

Advancements in treatment have significantly improved the quality of life and life expectancy for people with cystic fibrosis. Early diagnosis, comprehensive treatment plans, and supportive care can help manage symptoms, reduce complications, and enable individuals to live fulfilling lives.

A 2023 computer-model study projected a median survival of 71.6 years for people with two copies of F508del who take elexacaftor-tezacaftor-ivacaftor from age 12 or older — 33.5 years longer than with supportive care alone — and 82.5 years when the drug is started between ages 12 and 17. These figures are projections from a model, not observed survival.

Key Research Papers

  1. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519-2531. — doi:10.1016/s0140-6736(16)00576-6
  2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-1073. — doi:10.1126/science.2475911
  3. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819. — doi:10.1056/NEJMoa1908639
  4. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation (STRIVE). N Engl J Med. 2011;365(18):1663-1672. — doi:10.1056/NEJMoa1105185
  5. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR (TRAFFIC and TRANSPORT). N Engl J Med. 2015;373(3):220-231. — PubMed PMID: 25981758
  6. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689. — doi:10.1164/rccm.201207-1160oe
  7. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-642. — doi:10.1056/nejm199409083311003
  8. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA. 2003;290(13):1749-1756. — doi:10.1001/jama.290.13.1749
  9. Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation. Lancet. 2019;394(10212):1940-1948. — doi:10.1016/S0140-6736(19)32597-8
  10. Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del (EVOLVE). N Engl J Med. 2017;377(21):2013-2023. — doi:10.1056/nejmoa1709846
  11. Cystic Fibrosis Foundation Patient Registry. 2020 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation. 2021. Find on PubMed
  12. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16(1):45-56. — doi:10.1038/nrg3849
  13. Keating C, Yonker LM, Vermeulen F, et al. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025;13(3):256-271. — PubMed PMID: 39756424
  14. Rayment JH, Davies G, Gaffin JM, et al. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in children with cystic fibrosis aged 2-5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study. Lancet Respir Med. 2026 (online ahead of print). — PubMed PMID: 42710511
  15. Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros. 2023;22(4):607-614. — PubMed PMID: 36849331

Historical Background

Cystic fibrosis was first recognized as a distinct disease by Dorothy Hansine Andersen in 1938, who described its pathology in a landmark paper connecting pancreatic lesions with lung disease in children. The underlying genetic defect in the CFTR gene was identified in 1989 by Lap-Chee Tsui, John Riordan, and Francis Collins, opening the door to targeted molecular therapies.

PubMed Topic Searches

The following PubMed topic searches surface the current peer-reviewed literature on Cystic Fibrosis. Each link opens a live PubMed query; results update as new papers are indexed.

  1. PubMed: Search: cystic fibrosis CFTR
  2. PubMed: Search: cystic fibrosis modulator therapy
  3. PubMed: Search: ivacaftor tezacaftor elexacaftor
  4. PubMed: Search: cystic fibrosis lung transplantation
  5. PubMed: Search: cystic fibrosis pancreatic insufficiency
  6. PubMed: Search: cystic fibrosis sweat chloride test
  7. PubMed: Search: cystic fibrosis newborn screening
  8. PubMed: Search: cystic fibrosis pseudomonas aeruginosa
  9. PubMed: Search: cystic fibrosis nutritional management
  10. PubMed: Search: cystic fibrosis related diabetes
  11. PubMed: Search: cystic fibrosis airway clearance
  12. PubMed: Search: cystic fibrosis gene therapy

Back to Table of Contents

Connections

Back to Table of Contents